Calling for improved translation in nanomedical research

The use of nanoparticles as novel diagnostic and therapeutic tools has gained immense attention in the field of cancer management. Nano-based therapies offer numerous possibilities such as enhanced drug solubility and stability, extended circulation times, tissue, cell, organelle-specific targeting, early detection and monitoring of diseases, stimuli-controlled drug release and co-delivery of multiple agents, all contributing to a safer drug delivery with minimized dose-limiting side-effects [1]. Several nanomedicines bearing these features are already on the market with many others following in the pipeline.

[1]  Deniz A. Bölükbas,et al.  Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors. , 2015, ACS nano.

[2]  Deniz A. Bölükbas,et al.  Lung cancer nanomedicine: potentials and pitfalls. , 2015, Nanomedicine.

[3]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[4]  V. Venditto,et al.  Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.

[5]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[6]  Marilena Hadjidemetriou,et al.  Nanomedicine: Evolution of the nanoparticle corona. , 2017, Nature nanotechnology.

[7]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[8]  Mauro Ferrari,et al.  An injectable nanoparticle generator enhances delivery of cancer therapeutics , 2016, Nature Biotechnology.

[9]  Scott E McNeil,et al.  Translational considerations for cancer nanomedicine. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Marina A Dobrovolskaia,et al.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[11]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.